Rapid response to dupilumab in an adult patient with eosinophilic esophagitis and allergic asthma

Benjamin Klein; Regina Treudler

doi:10.5414/ALX02485E

Rapid response to dupilumab in an adult patient with eosinophilic esophagitis and allergic asthma

Allergol Select. 2024 Apr 5:8:78-81. doi: 10.5414/ALX02485E. eCollection 2024.

Authors

Benjamin Klein^{1

2}, Regina Treudler^{1

3}

Affiliations

¹ Leipzig Comprehensive Allergy Center LICA-CAC, Department of Dermatology, Venereology and Allergology, University of Leipzig, Leipzig, Germany.
² Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, and.
³ Institute of Allergology, Charité Universitätsmedizin Berlin, Berlin, Germany.

Abstract

Background: Eosinophilic esophagitis (EoE) is an inflammatory disease of the esophagus that belongs to the spectrum of Th2-mediated diseases. It is often associated with atopic comorbidities such as allergic asthma (AA) and poses a therapeutic challenge.

Case report: We report on a 43-year-old patient with EoE and AA who did not show sufficient therapeutic control despite standard therapy. We started treatment with dupilumab, whereupon both EoE and AA rapidly improved and complete symptom resolution could be documented. The response to dupilumab was assessed by laboratory monitoring and gastroscopy, which showed a reduction of markers of type II inflammation and eosinophilic infiltrates in the esophagus.

Summary: Our report emphasizes the effective and safe use of dupilumab as a treatment option for EoE with concomitant beneficial effects on AA.

Keywords: eosinophilic; esophagitis.

Publication types

Case Reports